Bayer, a German pharmaceutical and biotechnology giant, finds itself entangled in a legal quagmire as Roundup verdicts continue to accumulate, surpassing $4 billion in U.S. jury awards. Despite facing mounting pressure and financial setbacks, Bayer appears resolute in its decision not to settle, opting instead to pursue legal appeals.
This strategy, however, exposes the company to the possibility of enduring additional trials and substantial verdicts for years to come.
With at least 10 trials expected this year and nearly 50,000 Roundup lawsuits pending, the stakes are high for Bayer as it navigates the complexities of the U.S. legal system.
The Allegations
Plaintiffs in these lawsuits claim to have developed non-Hodgkin’s lymphoma and other forms of cancer as a result of using Roundup, either at home or in professional settings. Bayer vehemently denies these allegations, maintaining that Roundup is safe for use. The contentious legal battle has raised questions about the product’s safety and the responsibility of the company that inherited the lawsuits through its acquisition of U.S. agrochemical company Monsanto in 2018.
The Legal Landscape
The World Health Organization’s cancer research agency, in 2015, suggested that glyphosate, Roundup’s active ingredient, was likely capable of causing cancer, although it did not conclusively determine its real-world risk. Diverging opinions persist, as U.S. and European regulators have found that glyphosate likely does not cause cancer and have allowed its continued sale. This divergence in scientific opinions adds complexity to the legal proceedings, leaving room for both sides to present their case.
Shifting Fortunes
Bayer’s journey with Roundup trials initially seemed positive, with the company celebrating nine consecutive victories. However, the tide turned in October, as plaintiffs secured victories in California, Missouri, and Pennsylvania state courts. The most recent setback came with a substantial $2.25 billion verdict awarded to a Pennsylvania resident, John McKivison, marking the largest Roundup verdict to date. Bayer’s shares slumped more than 5% in response to this latest development.
Bayer’s Response and Strategy
In the face of these trial losses, Bayer remains resolute in its decision to appeal, expressing confidence in its ability to overturn the verdicts. The company points to previous successes in appeals, citing instances where it managed to significantly reduce jury verdicts. Notably, Bayer highlights three cases before 2020 where verdicts totaling over $1.4 billion were reduced to $132 million through appeals—a reduction of nearly 95%.
One key argument in Bayer’s arsenal is the limitation on punitive damages, with U.S. Supreme Court guidance suggesting they should not exceed nine times compensatory damages. While this argument may apply in some instances, the recent McKivison case awarded punitive damages eight times the compensatory damages, leaving room for Bayer to challenge the verdict on other grounds.
Bayer contends that recent trials have allowed expert witnesses for the plaintiffs to misrepresent the scientific evidence, a claim it is likely to leverage in appeals to overturn verdicts. Additionally, the company has been pursuing a legal argument centered on the approval of Roundup’s label by federal regulators years ago. Bayer asserts that this regulatory approval shields it from lawsuits related to alleged failure to warn consumers about potential cancer risks. Despite facing setbacks in bringing this argument before the U.S. Supreme Court, Bayer remains hopeful that pending appellate cases could reignite the possibility of a favorable outcome.
The Time-Consuming Legal Battle
Bayer’s chosen legal strategies share a commonality—they are protracted processes that could take years to unfold. The company’s confidence in eventually winning on the science and eliminating the entire litigation is juxtaposed against the reality of enduring continuous trial losses in the interim. The complexity of the legal landscape requires Bayer to win at both the state and federal levels, making it a high-stakes, bet-the-company scenario.
David Noll, a Rutgers Law School professor specializing in mass torts, aptly describes Bayer’s posture as “almost naturally a bet-the-company posture.” While Bayer is confident in its long-term prospects, the immediate impact involves substantial financial losses and a tarnished corporate image. The unpredictability of the legal system adds a layer of uncertainty, making it challenging for Bayer to accurately assess its future liabilities.
Failed Settlement Attempts
The option of settling the litigation looms over Bayer, but it is not a straightforward path. In 2020, the company agreed to a $10.9 billion settlement to resolve most pending Roundup lawsuits. However, a court rejected approval for a $2 billion plan to settle future cases in 2021. This setback prompted Bayer to withdraw Roundup from the home consumer market while continuing sales for professional and agricultural uses.
The rejection of the settlement plan indicates the challenges Bayer faces in reaching a comprehensive resolution. Even after a settlement, the company could be vulnerable to new lawsuits from individuals who developed cancer after exposure or those who used the product professionally. Fund manager Markus Manns of Union Investment warns that new plaintiffs could be knocking on Bayer’s door within one to two years of a settlement.
Conclusion
As Roundup verdicts pile up, Bayer’s gamble on the U.S. appeals courts reflects a high-stakes strategy that could define the company’s future. Despite facing over $4 billion in jury verdicts and losing 70% of its stock value since acquiring Monsanto in 2018, Bayer remains determined to prove the safety of Roundup through legal avenues. The scientific debate surrounding glyphosate adds complexity to the litigation, and the company’s legal arguments may take years to unfold.
While Bayer has successfully reduced verdicts in previous appeals, the magnitude of the Roundup litigation poses a substantial challenge. The ongoing legal battle exposes Bayer to financial losses, reputational damage, and a prolonged period of uncertainty. Whether the company’s bet on U.S. appeals courts will ultimately pay off remains to be seen, but the journey ahead promises a complex and protracted legal saga for one of the world’s largest pharmaceutical and biotechnology companies.